Valuation : Cara Therapeutics, Inc.

Market Cap 24.33M 20.96M 19.85M 17.99M 33.75M 2.32B 33.93M 236M 90.66M 1.18B 91.38M 89.37M 3.74B P/E 2023
-0.34x
P/E 2024 -0.39x
Enterprise Value 30.88M 26.6M 25.19M 22.83M 42.83M 2.95B 43.05M 299M 115M 1.5B 116M 113M 4.74B EV / Sales 2023
-0.82x
EV / Sales 2024 4.84x
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 20.97M 18.07M 17.11M 15.5M 29.09M 2B 29.24M 203M 78.13M 1.02B 78.75M 77.02M 3.22B 7.14M 6.15M 5.82M 5.28M 9.9M 682M 9.95M 69.15M 26.59M 347M 26.8M 26.22M 1.1B
Net income -119M -102M -96.69M -87.64M -164M -11.32B -165M -1.15B -442M -5.76B -445M -435M -18.2B -70.87M -61.06M -57.81M -52.4M -98.31M -6.77B -98.81M -687M -264M -3.44B -266M -260M -10.88B
Net Debt -57.59M -49.62M -46.98M -42.59M -79.89M -5.5B -80.3M -558M -215M -2.8B -216M -212M -8.85B 6.54M 5.64M 5.34M 4.84M 9.08M 625M 9.13M 63.42M 24.39M 318M 24.58M 24.04M 1.01B
Logo Cara Therapeutics, Inc.
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!